Presentation
Sigolène MEILHAC is Director of Research at INSERM, and Pasteur Vallery-Radot Prize awardee in 2018.
Sigolène MEILHAC is a developmental biologist and INSERM Research Director, leading since 2015 the team of Heart Morphogenesis jointly affiliated to the Institut Pasteur and Institut Imagine. Trained at the Ecole Normale Supérieure, she obtained a PhD under the supervision of M. Buckingham (Institut Pasteur) in 2003 and carried out post-doctoral work at the Gurdon Institute of Cambridge (UK), as a Marie Curie and EMBO fellow. She was recruited by the INSERM as a tenured researcher in 2006, and, with the support of the young researcher programme of the ANR in 2012, created a research group at the Institut Pasteur. Now located within the campus of the Hospital Necker-Enfants Malades, her team is part of the « ICaRP cardiology » network, that she coordinates to foster interactions between multi-disciplinary expertise in fundamental research and clinics. She is a member of the Board of Reviewing Editors of the journal eLife. She is involved in academic teaching and student supervision, develops scientific workshops for children. Sigolène Meilhac was recipient of the Pasteur Vallery-Radot price in 2018.
Resources & publications
-
Journal (source)J. Invest. Dermatol.
A TP63 mutation causes prominent alopecia with mild ectodermal dysplasia.
-
Journal (source)Br. J. Dermatol.
EBGene trial: patient preselection outcomes for the European GENEGRAFT ex viv...
-
Journal (source)Br. J. Dermatol.
EBGene trial: patient preselection outcomes for the European GENEGRAFT ex viv...
-
Journal (source)J. Invest. Dermatol.
Mutations in PERP Cause Dominant and Recessive Keratoderma.
-
Journal (source)Mol Ther Nucleic Acids
Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Usin...
-
Journal (source)Sci Transl Med
APOBEC mutation drives early-onset squamous cell carcinomas in recessive dyst...
-
Journal (source)J. Invest. Dermatol.
Intradermal Injection of Bone Marrow Mesenchymal Stromal Cells Corrects Reces...
-
Journal (source)J. Am. Acad. Dermatol.
Diacerein orphan drug development for epidermolysis bullosa simplex: A phase ...
-
Journal (source)J. Invest. Dermatol.
Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7)...
-
Journal (source)J. Invest. Dermatol.
Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fi...
-
Journal (source)J. Invest. Dermatol.
Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bull...
-
Journal (source)PLoS Genet.
KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
-
Journal (source)J. Exp. Med.
Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks...
-
Journal (source)J Allergy Clin Immunol
Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α a...
-
Journal (source)Expert Opin Emerg Drugs
Emerging drugs for the treatment of epidermolysis bullosa.
-
Journal (source)J Invest Dermatol
Drug Repurposing Reveals mTOR Inhibition as a Promising Strategy for Epidermo...